bioRxivBiophysics
Classifying drugs by their arrhythmogenic risk using machine learning
Abstract
Abstract.An undesirable side effect of drugs are cardiac arrhythmias, in particular a condition called torsades de pointes. Current paradigms for drug safety evaluation are costly, lengthy, and conservative, and impede efficient drug development. Here we combine multiscale experiment and simulation, high-performance computing, and machine learning to create an easy-to-use risk assessment diagram to quickly and reliable stratify the pro-arrhythmic potential of new and existing drugs. We capitalize on recent developments in machine learning and integrate information across ten orders of magnitude in space and time to provide a holistic picture of the effects of drugs, either individually or in combination with other drugs. We show, both experimentally and computationally, that drug-induced arrhythmias are dominated by the interplay of two currents with opposing effects: the rapid delayed rectifier potassium current and the L-type calcium current. Using Gaussian process classification, we create a classifier that stratifies safe and arrhythmic domains for any combinations of these two currents. We demonstrate that our classifier correctly identifies the risk categories of 23 common drugs, exclusively on the basis of their concentrations at 50% current block. Our new risk assessment diagram explains under which conditions blocking the L-type calcium current can delay or even entirely suppress arrhythmogenic events. Using machine learning in drug safety evaluation can provide a more accurate and comprehensive mechanistic assessment of the pro-arrhythmic potential of new drugs. Our study shapes the way towards establishing science-based criteria to accelerate drug development, design safer drugs, and reduce heart rhythm disorders.
- assay: electrophysiology
- research focus: drug response / drug discovery
- research focus: benchmarking
- approach: machine learning (classical)
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Assessing drug safety by identifying the axis of arrhythmia in cardiomyocyte electrophysiology
S. Heitmann, J. I. Vandenberg, A. P. Hill·bioRxiv·Apr 19, 2023
- Independent derivations of the axis of arrhythmia for predicting drug-induced torsades de pointes
Stewart Heitmann, Jamie I. Vandenberg, Adam Parker Hill·British Journal of PharmacologyPeer-reviewed·Jun 1, 2025
- AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: a loperamide case study
Paula Dominguez-Gomez, Alberto Zingaro, … Jazmín Aguado‐Sierra·Regulatory Toxicology and PharmacologyPeer-reviewed·Jun 1, 2026
- Early afterdepolarisation tendency as a simulated pro-arrhythmic risk indicator
B. McMillan, D. J. Gavaghan, G. Mirams·bioRxiv·Aug 15, 2017
- Transmural and rate-dependent profiling of drug-induced arrhythmogenic risks through in silico simulations of multichannel pharmacology
- Prediction of TdP Arrhythmia Risk Through Molecular Simulations of Conformation-specific Drug Interactions with the hERG K+, NaV1.5, and CaV1.2 Channels
Kyle C. Rouen, Kush Narang, … Igor V. Vorobyov·bioRxiv·Sep 25, 2025